Haematologic Technologies, Inc. (HTI) specializes in the isolation and characterization of high quality, human plasma proteins which are intended for in vitro research use. HTI's emphasis is focused on proteins involved in the regulation of blood coagulation and fibrinolysis, as well as the regulation of bone metabolism. The HTI product line consists of over 150 proteins including zymogens, enzymes, cofactors, and inhibitors as well as a complementary line of monoclonal and polyclonal antibodies. Additionally, HTI offers a broad line of services, which includes: custom protein purification, protein modification, assay development, contract manufacturing and contract research.
